<DOC>
	<DOCNO>NCT00836147</DOCNO>
	<brief_summary>This trial explore efficacy safety 250ng Juvista per Linear cm , administer intradermal injection follow excision ear lobe keloid . Keloids commonly occur ear pierce usually bilateral.One ear lobe treat Juvist one placebo .</brief_summary>
	<brief_title>Exploratory Study Efficacy Safety Juvista 250ng When Administered Following Excision Ear Lobe Keloids</brief_title>
	<detailed_description />
	<mesh_term>Keloid</mesh_term>
	<criteria>Subjects age 1885 year give write informed consent . Subjects bilateral ear lobe keloid scar comparable size suitable surgical excision result single wound ear lobe great 2cm long restricted skin , fat fibrous tissue ear lobe . Subjects , opinion investigator , clinically acceptable result laboratory test specify trial protocol ( see Protocol Section 6.3.2 ) . All laboratory test must perform within 28 day first trial dose administration . Female subject child bear potential use highly effective method ( ) contraception agree least screen visit one month administration final study dose . For purpose protocol , highly effective method ( ) contraception define consistently correctly used implant , injectables , combine oral contraceptive , sexual abstinence vasectomise partner . Subjects ear lobe keloid treat irradiation , cryosurgery , corticosteroid , pharmacological agent three month prior first trial dose administration . Subjects history bleed disorder . Subjects direct question and/or physical examination past present evidence eczema psoriasis local site administration , uncontrolled diabetes ( fast plasma glucose concentration consistently 7.0mmol 11 ( 126 mg dl1 ) , severely immunocompromised patient and/or malignant skin tumour e.g . melanoma , squamous basal cell carcinoma . Subjects skin disorder , relate keloid disease , chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial . Subjects history malignancy last 5 year . Subjects history hypersensitivity drug dressing use trial . Subjects take , take investigational product participate clinical trial three month prior first trial dose administration . Subjects undergoing investigation change management exist medical condition . Subjects , opinion Investigator , unlikely complete trial whatever reason . Female subject pregnant lactating . Subjects creatinine clearance ( CLcr ) 80ml/min less . Creatinine clearance determine serum creatinine level prestudy screen use follow formula . CLcr = 140 age ( year ) x Weight ( kg ) 72 x serum creatinine mg/dL [ x 0.85 female ] Subjects able undergo MRI scanning due medical history physical condition . Subjects previously receive treatment Juvista ( Avotermin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>